+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
FEMALE
ID07286266

Randomized Study Comparing Mocertatug Rezetecan with Standard Chemotherapy in Platinum-resistant Ovarian Cancer

Led by GlaxoSmithKline · Updated on 2026-10-15

450

Participants Needed

22

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying Mocertatug rezetecan Mo-Rez to see how it works in treating ovarian cancer that does not respond well to platinum-based therapies. This Phase 3 trial compares Mo-Rez to standard chemotherapy treatments while evaluating its safety, tolerability, and side effects. The study is sponsored by GlaxoSmithKline and focuses on platinum-resistant ovarian cancer, including specific tumor types confirmed by tissue testing. Participants will be randomly assigned to receive either Mo-Rez or one of several standard chemotherapy options chosen by their doctor, including Paclitaxel, Pembrolizumab with or without Bevacizumab, Pegylated liposomal doxorubicin PLD, Topotecan, or Gemcitabine. The treatments will be given according to standard administration methods, and participants may continue in the study for up to approximately 212 weeks to evaluate long-term outcomes. Throughout the study, participants will undergo regular assessments including tumor scans to measure disease progression and response, blood tests, and quality-of-life questionnaires. Researchers will monitor survival rates, side effects, vital signs, laboratory values, and immune responses to the drug. Safety monitoring and patient-reported outcomes will continue for the full duration of participation, which may last over four years.

CONDITIONS

Brief Title

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Research Team

U

US GSK Clinical Trials Call Center

E

EU GSK Clinical Trials Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here